Medical diagnostics company Guardant Health has sued rival Natera in California federal court for allegedly stealing trade ...

The lawsuit claims Natera aggressively recruited bioinformatics scientists from Guardant to “jumpstart its lagging position ...

Natera Inc. poached Guardant Health Inc. employees to steal trade secrets and jumpstart its “lagging position” in the early cancer test industry, according to a federal lawsuit. Former Guardant ...

Delaware federal judge reverses jury verdict in CareDx’s favour | Natera’s patents covering organ transplant testing ...

As of December 2024, Guardant held $840 million of cash and marketable securities. However, it burned through approximately $390 million in 2022, $345 million in 2023, and $275 million in 2024.

Scotiabank raised the firm’s price target on Guardant Health (GH) to $52 from $47 and keeps an Outperform rating on the shares. Guardant Health wrapped up 2024 on a high note, delivering 31% ...

In a report released today, Mark Massaro from BTIG reiterated a Buy rating on Guardant Health (GH – Research Report), with a price target of $60.00. The company’s shares closed yesterday at ...

Guardant Health has a 12 month low of $15.81 and a 12 month high of $50.89. The firm has a market capitalization of $5.30 billion, a P/E ratio of -12.04 and a beta of 1.32.

Shares of NASDAQ:GH opened at $42.44 on Monday. Guardant Health has a 52-week low of $15.81 and a 52-week high of $50.89. The company has a market capitalization of $5.24 billion, a P/E ratio of ...

Friday - Canaccord Genuity has increased the price target on Guardant Health (NASDAQ:GH) shares to $60, up from the previous $42, while maintaining a Buy rating on the stock. The ...